Core Insights - NeuroPace, Inc. has completed the repurchase of 5,270,845 shares from KCK Ltd., allowing KCK to sell all remaining shares it held in the company [1] - The repurchase was funded using proceeds from a recent underwritten public offering, which has strengthened NeuroPace's balance sheet and is expected to support operations until cash flow breakeven is achieved [1][2] - The company has terminated its current at-the-market offering program following the completion of the public offering [1] Financial Position - The recent financing has provided sufficient cash runway for NeuroPace to execute its long-range plan and achieve cash flow breakeven [2] - The company expressed gratitude to KCK Ltd. for its support over the years [2] Product and Market Focus - NeuroPace is dedicated to transforming the lives of individuals with epilepsy through its RNS System, which is the first commercially available brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - The RNS System aims to improve care standards for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3]

Company Overview - NeuroPace, Inc. is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy by reducing or eliminating debilitating seizures [3] - The company has developed the RNS System, which is the first and only commercially available brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - This platform aims to improve the standard of care for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3] Financial Reporting - NeuroPace will report its financial results for the fourth quarter and full year of 2024 after market close on March 4, 2025 [1] - A conference call will be held at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss these results [1] Investor Engagement - Investors can access the conference call via a live and archived webcast [2] - For those wishing to participate by telephone, the call can be accessed by dialing +1-877-407-3982 and referencing Conference ID 13751530 [2] - The webcast will be available for replay for at least 90 days after the event [2]

Core Viewpoint - NeuroPace, Inc. has successfully completed a public offering of 7,475,000 shares at a price of $10.00 per share, raising approximately $74.8 million in gross proceeds [1][2] Group 1: Offering Details - The offering included 975,000 shares sold due to the underwriters' full exercise of their option to purchase additional shares [1] - The net proceeds will be used primarily to repurchase 5,270,845 shares from significant stockholder KCK Ltd. at $9.40 per share [2] - Remaining proceeds will be allocated for general corporate purposes, including clinical trials, research and development, and working capital [2] Group 2: Management and Registration - J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners served as joint book-running managers for the offering, with Lake Street Capital Markets as the lead manager [3] - The shares were offered under a shelf registration statement effective since November 22, 2022, with a final prospectus supplement filed with the SEC [4] Group 3: Company Overview - NeuroPace is a medical device company focused on improving the lives of individuals with epilepsy through its RNS System, which provides personalized, real-time treatment [6]

Core Viewpoint - NeuroPace, Inc. has announced a public offering of 6,500,000 shares at a price of $10.00 per share, aiming to raise approximately $65 million before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on February 18, 2025, subject to customary closing conditions [1]. - NeuroPace has granted underwriters a 30-day option to purchase an additional 975,000 shares at the public offering price [1]. - The shares are being offered under a shelf registration statement filed with the SEC, effective since November 22, 2022 [4]. Group 2: Use of Proceeds - Approximately $49.5 million of the net proceeds will be used to repurchase 5,270,845 shares from significant stockholder KCK Ltd. at $9.40 per share [2]. - Remaining proceeds will be allocated for general corporate purposes, including clinical trials, research and development, administrative expenses, debt reduction, and working capital [2]. Group 3: Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on improving the lives of epilepsy patients through its RNS System, which provides personalized, real-time treatment [6].

Core Viewpoint - NeuroPace, Inc. plans to offer $65 million in common stock through an underwritten public offering, with a potential additional 15% option for underwriters [1][2]. Group 1: Offering Details - The public offering consists of $65 million worth of common stock, all offered by NeuroPace [1]. - NeuroPace will grant underwriters a 30-day option to purchase up to an additional 15% of the shares [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - A significant portion of the proceeds will be used to repurchase shares held by KCK Ltd. at the same price per share as the public offering [2]. - Remaining net proceeds will be allocated for general corporate purposes, including clinical trials, research and development, administrative expenses, debt reduction, and working capital [2]. Group 3: Management and Registration - J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners are joint book-running managers for the offering, with Lake Street Capital Markets as the lead manager [3]. - The shares are being offered under a shelf registration statement effective since November 22, 2022, with a prospectus supplement to be filed with the SEC [4]. Group 4: Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on improving the lives of epilepsy patients through its RNS System, which provides personalized, real-time treatment [6].

Core Insights - NeuroPace, Inc. is focused on transforming the lives of individuals with epilepsy through innovative medical devices [3] - The company announced that an abstract from its Post-approval Study of the RNS System will be presented at the AAN 2025 Annual Meeting [1] Presentation Details - The presentation titled "Multicenter Post-approval Study of the RNS System in Focal Epilepsy" will be delivered by Dr. Dawn Eliashiv [2] - The session is scheduled for April 7, 2025, at 5:06 PM PT [2] Company Overview - NeuroPace is based in Mountain View, California, and specializes in developing the RNS System, which is the first commercially available brain-responsive platform for epilepsy treatment [3] - The RNS System aims to provide personalized, real-time treatment at the source of seizures, potentially improving care for patients with drug-resistant epilepsy [3]

– 2025 revenue guidance of $92 million to $96 million – – 2025 gross margin guidance of 73% to 75% – – Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today issued 2025 financial guidance targets at an in-person and virtual Investor Day today in New York, New York (a replay can be viewed virtually h ...

NeuroPace, Inc. (NPCE) shares soared 9.1% in the last trading session to close at $13.06. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.6% gain over the past four weeks.NeuroPace recorded a strong price rise on investors’ optimism surrounding the company’s announcement of preliminary fourth quarter and full year 2024 financial results. The company expects total revenue for fourth quarter to be between $21.0 million and $21.5 ...

Core Insights - NeuroPace, Inc. announced preliminary unaudited revenue expectations for Q4 2024 between $21.0 million and $21.5 million, and for the full year 2024 between $79.4 million and $79.9 million, indicating growth of 17% to 19% for Q4 and 21% to 22% for the full year compared to 2023 [1][8] Financial Performance - The company achieved over 20% revenue growth in 2024, with strong gross margin performance and reduced cash burn while investing in long-term growth [4] - Cash and short-term investments as of December 31, 2024, are expected to be $52.8 million, with total shares of common stock outstanding anticipated to be 30,145,039 [8] Management and Board Updates - Scott Huennekens was appointed to the Board of Directors effective January 6, 2025, bringing extensive management and investment experience in the medtech sector [5][6] - Huennekens has a successful track record with over 20 medical device companies, contributing to significant shareholder value [7] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, and will host an Investor Day on January 28, 2025, in New York City [14]

Core Viewpoint - The upgrade of NeuroPace to a Zacks Rank 2 (Buy) reflects an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [6][12]. Earnings Estimates - Analysts have raised their earnings estimates for NeuroPace, with the Zacks Consensus Estimate increasing by 7.9% over the past three months [4]. - The company is expected to earn -$1 per share for the fiscal year ending December 2024, representing a year-over-year change of 21.3% [10]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [3]. - NeuroPace's upgrade places it in the top 20% of Zacks-covered stocks, indicating its strong earnings estimate revision feature [5][12]. - The Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings, ensuring that only the top 5% of stocks receive a 'Strong Buy' rating [11]. Market Implications - The change in earnings estimates is strongly correlated with near-term stock price movements, influenced by institutional investors who adjust their valuations based on these estimates [8]. - Tracking earnings estimate revisions can be beneficial for investment decisions, as empirical research shows a strong correlation between these revisions and stock movements [9].